CA2619889C - Use of itraconazole and salts thereof for treating cancer - Google Patents

Use of itraconazole and salts thereof for treating cancer Download PDF

Info

Publication number
CA2619889C
CA2619889C CA2619889A CA2619889A CA2619889C CA 2619889 C CA2619889 C CA 2619889C CA 2619889 A CA2619889 A CA 2619889A CA 2619889 A CA2619889 A CA 2619889A CA 2619889 C CA2619889 C CA 2619889C
Authority
CA
Canada
Prior art keywords
hedgehog
cell
subject
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2619889A
Other languages
English (en)
French (fr)
Other versions
CA2619889A1 (en
Inventor
Philip Arden Beachy
Jun Liu
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2619889A1 publication Critical patent/CA2619889A1/en
Application granted granted Critical
Publication of CA2619889C publication Critical patent/CA2619889C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2619889A 2005-08-22 2006-08-22 Use of itraconazole and salts thereof for treating cancer Expired - Lifetime CA2619889C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71011705P 2005-08-22 2005-08-22
US60/710,117 2005-08-22
PCT/US2006/032952 WO2007024971A2 (en) 2005-08-22 2006-08-22 Hedgehog pathway antagonists to treat disease

Publications (2)

Publication Number Publication Date
CA2619889A1 CA2619889A1 (en) 2007-03-01
CA2619889C true CA2619889C (en) 2020-05-05

Family

ID=37772335

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2619889A Expired - Lifetime CA2619889C (en) 2005-08-22 2006-08-22 Use of itraconazole and salts thereof for treating cancer

Country Status (7)

Country Link
US (1) US8653083B2 (enExample)
EP (2) EP1919480B1 (enExample)
JP (1) JP5435946B2 (enExample)
AU (1) AU2006283040B2 (enExample)
CA (1) CA2619889C (enExample)
ES (1) ES2403006T3 (enExample)
WO (1) WO2007024971A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
US20240360111A1 (en) * 2011-09-07 2024-10-31 The Johns Hopkins University Itraconazole analogs and use thereof
US9072660B2 (en) 2011-09-09 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Topical itraconazole formulations and uses thereof
WO2013130625A1 (en) * 2012-02-27 2013-09-06 Basil Rigas Phospho-ester derivatives and uses thereof
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
ITRM20130366A1 (it) 2013-06-25 2014-12-26 Univ Roma La Sapienza Multitarget hedgehog pathway inhibitors and uses thereof
WO2015116947A1 (en) 2014-02-01 2015-08-06 University Of Connecticut Itraconazole analogues and methods of use thereof
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
WO2016196614A1 (en) * 2015-06-01 2016-12-08 University Of Kentucky Research Foundation Chloroquine induction of par-4 and treatment of cancer
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
US20180193335A1 (en) * 2015-10-12 2018-07-12 Vikash J. BHAGWANDIN Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
AU2018253189A1 (en) * 2017-04-12 2019-12-05 Vikash J. BHAGWANDIN Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
WO2018211007A1 (en) * 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
CA3073228A1 (en) 2017-08-20 2019-02-28 University Of Connecticut Azole analogues and methods of use thereof
CN110279696A (zh) * 2019-07-31 2019-09-27 中国医学科学院皮肤病医院 伊曲康唑在制备抑制肿瘤转移药物中的应用
WO2021030174A1 (en) 2019-08-09 2021-02-18 University Of Connecticut Truncated itraconazole analogues and methods of use thereof
CN113521071A (zh) * 2021-07-22 2021-10-22 广州医科大学 氯喹那多的新应用
CN114081883B (zh) * 2021-11-04 2023-02-28 武汉科技大学 氯喹那多在制备抗肿瘤药物中的应用
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
WO2024249959A1 (en) * 2023-06-02 2024-12-05 University Of Massachusetts Medical School Compositions reducing the expression or activity of c1 galt1 for treating ewing sarcoma

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4824829A (en) * 1984-08-15 1989-04-25 American Cyanamid Company Non-dusting antibiotic, anticoccidial premix compositions and a process for their manufacture
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
EP0631578B1 (en) 1992-03-18 2001-05-23 Janssen Pharmaceutica N.V. Itraconazole and saperconazole stereoisomers
JPH0782162A (ja) 1993-09-10 1995-03-28 Pola Chem Ind Inc 皮膚外用剤
JPH0782163A (ja) 1993-09-10 1995-03-28 Pola Chem Ind Inc 肝障害治療剤及びこれを含有する組成物
NZ278765A (en) 1993-12-30 1998-05-27 Harvard College Vertebrate proteins involved in spatial arrangements of differentiated tissues called hedgehog proteins, their production and use
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
AUPN033894A0 (en) * 1994-12-29 1995-01-27 Rowe, J.B. Prevention of adverse behaviour in humans and animals
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
US6509038B2 (en) * 1996-05-20 2003-01-21 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
PL191181B1 (pl) 1997-12-31 2006-03-31 Choongwae Pharma Corp Sposób wytwarzania doustnego preparatu itrakonazolu i doustny preparat itrakonazolu
US6277566B1 (en) 1998-02-13 2001-08-21 Phillip A. Beachy Method for identifying a hedgehog-mediated phosphorylation state dependent transcription factor
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6867216B1 (en) 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
JP5067986B2 (ja) * 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
ES2157731B1 (es) 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
US6552026B2 (en) 1999-06-14 2003-04-22 Basf Aktiengesellschaft 6-phenyl-pyrazolopyrimidines
US6552016B1 (en) * 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE19963052A1 (de) * 1999-12-24 2001-06-28 Bayer Ag Verwendung von Azolen zur Prävention von Hautkrebs
ES2623711T3 (es) 2000-10-13 2017-07-12 Curis, Inc. Antagonistas de hedgehog, procedimientos y usos relacionados con los mismos
AU2002217911A1 (en) 2000-11-28 2002-06-11 Curis, Inc. Basal cell carcinoma cultures, methods related thereto and their use
BR0117063A (pt) * 2001-07-02 2004-07-27 Sinan Tas Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
US6946137B2 (en) 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
EP1631290A2 (en) * 2003-05-23 2006-03-08 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
EP1631279A4 (en) 2003-05-30 2007-03-14 Combinatorx Inc COMBINED THERAPY FOR THE TREATMENT OF NEOPLASMS
US20050049207A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors

Also Published As

Publication number Publication date
US8653083B2 (en) 2014-02-18
WO2007024971A2 (en) 2007-03-01
WO2007024971A3 (en) 2008-01-03
JP2009506054A (ja) 2009-02-12
EP2404602A1 (en) 2012-01-11
CA2619889A1 (en) 2007-03-01
AU2006283040B2 (en) 2011-08-25
ES2403006T3 (es) 2013-05-13
EP1919480A4 (en) 2009-07-22
JP5435946B2 (ja) 2014-03-05
US20090203713A1 (en) 2009-08-13
AU2006283040A1 (en) 2007-03-01
EP1919480B1 (en) 2013-01-16
EP1919480A2 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
AU2006283040B2 (en) Hedgehog pathway antagonists to treat disease
Li et al. Quercetin attenuates trauma-induced heterotopic ossification by tuning immune cell infiltration and related inflammatory insult
Shacka et al. Kainic acid induces early and transient autophagic stress in mouse hippocampus
EP1496905B1 (en) Modulators of hedgehog signaling pathways, compositions and uses related thereto
US7652043B2 (en) WNT pathway antagonists
US7816369B2 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
US20050113460A1 (en) Compositions and methods relating to novel compounds and targets thereof
US8486400B2 (en) Methods of inhibiting unwanted cell proliferation using an antibody that binds to sonic hedgehog and inhibits hedgehog signaling
CN101626758A (zh) 用于治疗癌症的lbh589和其他治疗剂的组合
WO2005033288A2 (en) Hedgehog pathway antagonists
US20130274233A1 (en) Modulators of hedgehog signaling pathway
JP2003511411A (ja) ヘッジホッグシグナル伝達経路のメディエーター、それらと関連する組成物及び利用
CA2884454C (en) Orvepitant and uses thereof
Chen et al. D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone‐induced apoptosis through inhibition of caspase‐and JNK‐dependent pathways
JP2008505913A (ja) 新規化合物およびこれらの標的に関する組成物ならびに方法
EP2945646A1 (en) Estrogen receptor inhibitors
KR102712565B1 (ko) Gabaa 수용체 리간드
Diaz-Ruiz et al. Cyclosporin-A inhibits inducible nitric oxide synthase activity and expression after spinal cord injury in rats
Bao et al. 17Beta-estradiol differentially protects cortical pericontusional zone from programmed cell death after traumatic cerebral contusion at distinct stages via non-genomic and genomic pathways
Tao et al. The role of activating transcription factor 6 in hydroxycamptothecin-induced fibroblast autophagy and apoptosis
AU2011253561B2 (en) Hedgehog pathway antagonists to treat disease
O'Neill et al. 5-HT1B/D receptor agonist, SKF99101H, induces locomotor hyperactivity in the guinea pig
US20100048577A1 (en) Method for treating benign prostate hyperplasia using resveratrol
CA2261676A1 (en) Method for treating excessive aggression
KR20220043047A (ko) 스핑고신-1-인산 수용체 효능제의 용도

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240816

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240816